anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The spatiotemporal superposition of two independent and opposite beams of laser generates a constructive interference pattern that increases the therapeutic effects in the irradiated tissue. Patient suffering pain from diagnosed carpal tunnel syndrome will receive conventional or interferential laser therapy. This is a comparative randomized and double blind clinical study. Two identical lasers in near infrared range will be used. Frequency of sessions: daily. Irradiated technique: manual, contact and punctual. Pain will be evaluated by visual analog scale at rest and during analytical wrist movement. Disability will be evaluated by the DASH and BOSTON questionnaire. Evaluation will take place at pre and post-treatment times.
Postpartum infection is a major cause of maternal morbidity and prolonged hospitalization, and places a large burden on the healthcare system with an additional cost of $3,700 (Olsen et al., 2010). Surgical site infection (SSI) is one of the most common post-operative complications following cesarean section, with an incidence of 3-15% worldwide (Zuarez-Eaaston et al., 2017). Wound dressings that are applied after closure of a surgical incision may help healing by providing physical support, protection from external contaminants, and by absorbing exudate (Dumville et al., 2016). A new FDA-approved microbicidial liquid adhesive, Steri3X, has been shown to reduce the incidence of pin-tract infection by 100% in a randomized-controlled trial following external fixation in patients undergoing reconstructive surgery for deformity correction (Pema, 2020). Steri3X is reported to be effective against S. aureus (both MSSA and MRSA), Candida albicans, E. coli, P. aeruginosa, and Candida auris, which are common organisms involved in dermatological infections. The most common organisms responsible for cesarean section SSI include enteric gram negative bacilli, enterococci, and group B streptococcus (Gur et al., 2015). The advantage of this polymer following C-sections is unknown, and a larger study is needed to provide a more robust analysis. This study aims to determine the effect of Steri3X on the incidence of cesarean section SSI at Regional One Hospital.
Up to 5 dose levels \[0.3, 1.0, 3.0, 10.0, and 20.0 milligrams per kilogram (mg/kg)\] will be evaluated sequentially. Participants will receive GIGA-564 intravenously over at least 60 minutes on Day 1 of every 3 weeks (3 weeks = 1 cycle) for up to 4 cycles until time of confirmed disease progression, unacceptable toxicity, or other reason for treatment discontinuation.
OBJECTIVE: To examine the associations between (i) various types of physical activity and the risk of back pain incidence, and (ii) the influence of substituting sedentary behaviours with physical activities on back pain incidence. DESIGN: A prospective cohort study. METHODS: We analyzed UK Biobank data collected from 365,307 participants who were free of back pain at baseline. The exposures were total, light, moderate and vigorous physical activity, and sedentary behaviours. The outcome was back pain incidence. The main statistical models were the Cox proportional hazard model and the isotemporal substitution model. RESULTS: In the follow-up time (median, 12.97 years; inter-quartile range, 12.10-13.71), 25,189 individuals developed back pain. The associations between all types of physical activity and incident back pain were significantly non-linear (p < 0.001) among the general population and other subgroups. High physical activity was associated with a decreased risk of back pain compared with no physical activity. The lowest risk occurred in the 1801-2400 MET-min/week subgroup of total physical activity (HR 0.64, 95% CI 0.59-0.69), approximately consisting of 1200, 600, and 600 MET-min/week of light, moderate and vigorous physical activity, respectively. Extremely high vigorous physical activity was related to high risk, specifically in males (HR 1.13, 95% CI 1.02-1.25). Replacing 1 hour/day of sedentary behaviours with an equal time of physical activity reduced the risk of incident back pain by 2%-8% (p < 0.05). CONCLUSION: Physical activity was related to a reduced risk of back pain incidence (except over-high vigorous physical activity). Substituting sedentary behaviours with physical activities reduced the risk of future back pain.
The invention discloses an Uncaria macrophylla Wall. decoction piece and a preparation method thereof. The Uncaria macrophylla Wall. decoction piece is prepared from 70 to 90 portions by weight of Uncaria macrophylla Wall., 0.8 to 1.2 portions by weight of goldthread root, 0.2 to 0.3 portions by weight of licorice root, 3 to 7 portions by weight of Chinese wolfberry, 2 to 4 portions by weight of longspur epimedium, 1 to 3 portions by weight of nettle and 3 to 7 portions by weight of brown sugar. The Uncaria macrophylla Wall. decoction piece is a health product with effects of nourishing yin and tonifying yang, soothing channels and activating collaterals, clearing heat and removing toxins, and improving semen and protecting kidney.
Vitamin D is a fat-soluble vitamin used by the body for normal bone development and maintenance by increasing the absorption of calcium, magnesium, and phosphate. Vitamin D also plays a role in the nervous system, musculoskeletal system and immune system. Vitamin D deficiency has been linked with diverse health conditions including diabetes, cardiovascular diseases, breast, colorectal and prostate cancer, dementia, depression, erectile dysfunction, osteoporosis, and bone disorders. Vitamin D deficiency is a global healthcare challenge. To overcome vitamin D deficiency, a daily vitamin D supplementation of 200-1000 IU or a high dosage from 25000 to 200000 IU for 4-6 weeks, is normally recommended.

Vitamin D supplements are available over the counter in different delivery vehicles (formulations) to reach the circulatory system. In the present study the investigators aim to evaluate the pharmacokinetics of an orodispersible vitamin D supplement vs a conventional oral soft gelatin capsule, in vitamin D deficient healthy adults to assess how different vitamin D supplement formulations can efficiently overcome the vitamin D deficiency.
This cohort includes patients diagnosed with primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) who have undergone suprachoroidal silicone tube (SST) shunt implantation. The study focuses on assessing the long-term safety and efficacy of the SST shunt, monitoring intraocular pressure (IOP) control, endothelial cell count (ECC) changes, and any adverse events over an extended follow-up period. This observational cohort includes patients aged 41-88 years, treated with the SST shunt either alone or in combination with cataract surgery, and meeting the inclusion criteria from a prior retrospective study.
Non-Asian healthy participants will receive 3 single doses of JNJ-64457744 as an oral formulation in 3 intervention periods (to assess inter-subject PK-PD) matching the doses evaluated in Cohorts A, C and E for Cohort G and Cohorts B, D and F for Cohort H, under fasted conditions on Day 1. Cohort H will be optional for Intervention period 3.
PURPOSE:To obtain the titled substrate having the form of beads and composed of irregularly intertwined regenerated collagen fibrils having specific diameter and an aqueous solution existing between said collagen fibrils. CONSTITUTION:An aqueous solution of collagen is dispersed in a water-immiscible organic solvent (e.g. toluene, carbon tetrachloride, etc.) in the form of a number of small droplets to obtain an emulsion. A water-miscible organic solvent and an alkali (e.g. ammonia, disodium hydrogen phosphate, etc.) are added simultaneously or successively to the above emulsion to solidify said droplets. The process gives a substrate containing regenerated collagen fibrils, and having the form of beads composed of irregularly intertwined regenerated collagen fibrils having a diameter of 10-500mum and an aqueous solution exsisting between the regenerated collagen fibrils. The content of the collagen fibril is 20- 0.01wt%. The product can be used for the determination of the agglutination activity of blood platelet.
We investigated the impact of drainage retinotomy on the outcome of pars plana vitrectomy for repair of rhegmatogenous retinal detachment (RRD). This study was a retrospective observational multicenter study. All patients were registered with the Japan-Retinal Detachment Registry. We analyzed 1887 eyes with RRD that had undergone vitrectomy and were observed for 6 months between February 2016 and March 2017. We compared the baseline characteristics and postoperative outcomes between eyes with and without drainage retinectomy. We then performed propensity score matching using preoperative findings as covariates to adjust for relevant confounders. Of 3446 eyes, 1887 met the inclusion criteria. Among them, 559 eyes underwent vitrectomy with drainage retinotomy, and 1328 eyes underwent vitrectomy without drainage retinotomy. After propensity score matching, each group comprised 544 eyes. There was no significant difference between the two groups in BCVA at 6 months after vitrectomy (0.181 vs. 0.166, P = 0.23), the primary anatomical success rate (6.3% vs. 4.4%, P = 0.22), or the rate of secondary surgery for ERM within 6 months (1.5% vs. 1.3%, P = 1.0). Drainage retinectomy does not increase the risk of decreased postoperative BCVA, surgical failure, or secondary surgery for ERM within six months outcomes.
In the procedure a substructure (4) is produced by modelling directly on a master model (1) to which has been applied a layer of distance material (2) and a layer of separation material (3). After drying of the master model (1) with applied substructure material for one minute at 80 °C the substructure material (4) can be removed from the master model (1) as an independent substructure, which is heat treated first by heating to 500 °C for at most 10 minutes, whereby the bonding agent is removed, and thereafter by heating to 1120 °C for 2 hours, whereby the material is sintered. After cooling the substructure (4) is checked on the master model (1), whereafter a layer of glass is applied and thereafter heated to 1100 °C for 2-4 hours whereby an infiltration of glass in the substructure material takes place. After removal of the excess glass a ceramic can be applied in the known manner. The separation material (2) consists of a mixture of completely combustible plasticine and chloroform in a mixing ratio enabling the material to be applied with a brush at 22 °C, but to harden at approx. 20 °C. The substructure material (4) consists of demineralised water, cellulose powder, sugar and oxide ceramic.
The efficacy of Lynparza was evaluated in OlympiAD (NCT02000622), an open-label randomized (2:1) study in patients with gBRCAm HER2-negative metastatic breast cancer. Patients were required to have received treatment with an anthracycline (unless contraindicated) and a taxane, in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor-positive disease must have progressed on at least 1 endocrine therapy (adjuvant or metastatic), or have disease that the treating healthcare provider believed to be inappropriate for endocrine therapy. Patients with prior platinum therapy were required to have no evidence of disease progress during platinum treatment. No prior treatment with a PARP inhibitor was permitted. Patients were randomized to Lynparza tablets 300 mg orally twice daily or healthcare provider’s choice of chemotherapy (capecitabine, eribulin, or vinorelbine, at standard doses) until progression or unacceptable toxicity. Randomization was stratified by prior use of chemotherapy for metastatic disease (yes vs no), hormone receptor status (hormone receptor positive vs triple negative), and previous use of platinum-based chemotherapy (yes vs no). The major efficacy outcome measure was PFS assessed by blinded independent central review (BICR) using RECIST version 1.1.

A total of 302 patients were randomized, 205 to Lynparza and 97 to chemotherapy. Among the 205 patients treated with Lynparza, the median age was 44 years (range: 22 to 76), 65% were White, 4% were males and all the patients had an ECOG PS of 0 or 1. Approximately 50% of patients had triple-negative tumors and 50% had estrogen receptor and/or progesterone receptor positive tumors and the proportions were balanced across treatment arms. Patients in each treatment arm had received a median of 1 prior chemotherapy regimen for metastatic disease; approximately 30% had not received a prior chemotherapy regimen for metastatic breast cancer. Twenty-one percent of patients in the Lynparza arm and 14% in the chemotherapy arm had received platinum therapy for metastatic disease. Seven percent of patients in each treatment arm had received platinum therapy for localized disease. 

Of the 302 patients randomized onto OlympiAD, 299 were tested with the BRACAnalysis CDx® and 297 were confirmed to have deleterious or suspected deleterious gBRCAm status; 202 were randomized to the Lynparza arm and 95 to the healthcare provider’s choice of chemotherapy arm.

A statistically significant improvement in PFS was demonstrated for the Lynparza arm compared to the chemotherapy arm. Efficacy data for OlympiAD are displayed in Table 23 and Figure 8. Consistent results were observed across patient subgroups defined by study stratification factors. An exploratory analysis of investigator-assessed PFS was consistent with the BICR-assessed PFS results.

Figure 8 Kaplan-Meier Curves of Progression-Free Survival - OlympiAD
The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus Omega 3 supplementation, the dosage was 2 capsules per day, containing 1.5 g of omega 3, of which 1000 mg were EPA and 500mg DHA. The omega 3 capsules were obtained from the same batch.
PROBLEM TO BE SOLVED: To obtain an oral cavity composition which has preferable texture and is expected to have high plaque-removing effect by formulating a β-1,3- glucan thereinto. SOLUTION: This composition contains a β-1,3-glucan [e.g. curdlan (polysaccharides which are homopolymers containing glucose combined by β-1,3-linkage and are produced from Alcaligenes faecalis and the genus Agrobacterium bacteria) and the like]. When the curdlan is used, if the amount is rich in curdlan, the crisp and little sticky texture is formed and if the amount is not rich, the sticky texture is formed. Ordinarily, curdlan is preferably utilized in an amount of 0.5-6 wt.% based on the whole weight of composition. Further, in order to formulate curdlan with an oral composition, the paste-like curdlan formed by heating an aqueous dispersion solution of curdlan at 40-60 deg.C is used.
NEW MATERIAL:A human monocyto growth factor capable of inducing differentiation and growth of human monocyto. USE:An infection preventive, an immunostimulant and anticancer agent. PREPARATION:For example, a culture filtrate of human ling cancer cell strain T3M-30Lu is collected and, after removal of low molecular weight components by a hollow fiber filter, concentrated and then adjusted to pH7.5. Ammonium sulfate is added thereto and the precipitate generated by the saturated ammonium sulfate of 30-60 wt.% is collected. The collected precipitate is dissolved in a trishydrochloric acid buffer solution (pH7.5) and substituted to the gel filtration method for collection of fractions having a monocyto growth factor activity. The collected fractions are subjected to the ion-exchange chromatography and then eluted by a NaCl concentration slope of 0-200mM and the resultant active fractions are subjected to the reversed phase high performance liquid chromatography and the eluted by a liner concentration slope of 0-99wt.% acetonitrile against 0.1wt.% trifluoroacetic acid, thus obtaining the objective human monocyto growth factor consisting of a proteinaceous substance having 21000 molecular weight and capable of inducing differentiation and growth of human monocyto.
The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
After standard general anesthetic mask induction, 0.5 ml of blood will be drawn for genetic analysis when the intravenous catheter is sited. A member of the research team will manually transport an appropriately-labeled blood collection tube to the Department of Anesthesiology Perioperative Genomics Laboratory for storage and further preparation for genetic analysis. The samples will be stored until the investigators have enough to process. The results will be stored in a secure database. The surgical procedure, anesthesia technique, intraoperative analgesia treatment and initial postoperative analgesia treatment will be standardized.Upon arrival in the Post-Anesthesia Care Unit(PACU), the child will be connected to standard monitors as per standard of care. Pain scores will be recorded on a scale of 0-10 (FLACC, Face, legs,activity, cry, consolability scale) scale. A member of the research team will apply the skin conductance (SC) monitor on the child's hand or foot.This will be used to measure SC values that will be saved on a laptop computer and the SC data will be analyzed off-line.
The current standard of care in patients with refractory bleeding from their peptic ulcers and other non-variceal causes has not been defined. An International Consensus Group recommends a surgical consult when endoscopic treatment has failed and TAE should be considered as an alternative. The European guidelines recommend the use of either surgery or angiographic embolization. There has not been a fully published RCT that compares angiographic treatment to surgery in those with refractory bleeding. Several comparative series mostly retrospective and their meta-analyses suggest that outcomes following TAE would not be dissimilar to those after surgery. Common to these reports, TAE is associated with a higher rate of further bleeds. In our meta-analysis , the pooled rate of further bleeds after TAE was 51/178(32%) compared to that of 26/241 (14.9%) after surgery. A high rate of further bleeding can be understood because of a rich vascular supply to peptic ulcers especially those in the bulbar duodenum. A bulbar ulcer receives dual arterial supply from celiac and superior mesenteric arteries. Embolization to these arteries can therefore be challenging. In a population-based study from northern Europe that included 282 patients (97 TAE and 185 surgery), the overall hazard of deaths after TAE decreased by 1/3 when compared to surgery. Many argue that TAE is preferred over surgery in the algorithm of management.

The use of OTSC has emerged as an alternative before TAE which is often considered most definitive. A multicenter randomized controlled trial that compared OTSC and standard endoscopic treatment mostly through-the-scope clips in patients with refractory bleeding peptic ulcers; 66 patients were randomized and control of bleeding over 30 days was better with the use of OTSC (15.2% vs. 57.6%). A Mayo Clinic group reported OTSC treatment in 67 high risk lesions defined by those near an arterial complex (bulbar or angular/lesser curve ulceration) with an artery larger than 2 mm, deep excavated fibrotic ulcer with major stigmata and those that failed standard endoscopic therapy (through-the-scope clips and/or thermal device); 47 (70.1%) remained free of further bleeds at day 30 10.
FIELD: organic chemistry. SUBSTANCE: product: 3-(1,2-benzisoxazole-3-yl)-4-pyridamines of the general formula I (R 1 ), where R 2  and   - hydrogen or lower alkyl. Compounds of the general formula I are synthesized by cyclization of corresponding substituted o-halogenphenylmethaneoxime in the presence of base in the medium of lower alcohol. Synthesized compounds are used in medicine. EFFECT: improved method of synthesis of compounds indicated above. 3 tbl
Peripheral venous catheter (PVK) is applied to patients who apply to the hospital due to outpatient chemotherapy and need to receive treatment by intravenous route. This application is carried out by nurses. During their education, nurses receive theoretical and practical training on PVC applications. Nurses; They are the primary health professionals who are responsible for determining the PVC site, deciding on the catheter number to be used, applying the correct technique, performing the recommended intravenous (IV) interventions, following the complications that may develop by performing the necessary controls, ensuring the continuity of the application and providing catheter care.

The effective application of interventions such as transfusion of intravenous fluids, chemotherapy drugs, blood and blood products, and total parenteral feeding in cancer patients is provided by PVK. The application of PVC is a necessity for the treatment of the individual receiving treatment and may cause pain, deterioration in comfort and dissatisfaction. Although the widespread use of peripheral venous catheters provides great benefits, it has been reported that undesirable events such as phlebitis, infiltration, obstruction, leakage, and rarely infection occur when applied incorrectly and inadequately. In order for peripheral venous catheters to be used effectively in treatment, it is important to fix them with the correct technique. Detection becomes more important in the use of chemotherapy agents. The patches used for fixation adhere to the glove and are difficult to remove from the patient's skin. Therefore, both the nurse and the patient feel discomfort. For this reason, it would be appropriate to use a material that can be easily torn off with a glove, does not adhere to the glove, and fixes the patient's catheter well. This product should also be able to be easily removed without harming the patient's skin.
Clients in the treatment group received the usual floating support service as described for the control group together with feedback. The support workers received feedback from the clients through the ORS and SRS scales of the feedback tool (Bargmann and Robinson 2011). The support worker evaluated the progress of the outcome for the client and the alliance between the support worker and the client from session to session.